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The ALL-1 gene is directly involved in 5–10% of acute lymphoblastic
leukemias (ALLs) and acute myeloid leukemias (AMLs) by fusion to
other genes or through internal rearrangements. DNA microarrays
were used to determine expression profiles of ALLs and AMLs with
ALL-1 rearrangements. These profiles distinguish those tumors from
other ALLs and AMLs. The expression patterns of ALL-1-associated
tumors, in particular ALLs, involve oncogenes, tumor suppressors,
antiapoptotic genes, drug-resistance genes, etc., and correlate with
the aggressive nature of the tumors. The genes whose expression
differentiates between ALLs with and without ALL-1 rearrangement
were further divided into several groups, enabling separation of
ALL-1-associated ALLs into two subclasses. One of the groups in-
cluded 43 genes that exhibited expression profiles closely linked to
ALLs with ALL-1 rearrangements. Further, there were evident differ-
ences between the expression profiles of AMLs in which ALL-1 had
undergone fusion to other genes and AMLs with partial duplication
of ALL-1. The extensive analysis described here pinpointed genes that
might have a direct role in pathogenesis.
Chromosome band 11q23 is a region of recurrent rearrange-ments in human acute leukemias. These rearrangements, usu-
ally in the form of reciprocal chromosome translocations, affect
5–10% of children and adults with acute lymphoblastic leukemia
(ALL) and acute myeloblastic leukemia (AML). The most com-
mon translocations are t(4;11) and t(9;11), accounting for 40% and
27%, respectively, of all 11q23 rearrangements. There is a strong
association between leukemia phenotype and particular rearrange-
ments. Thus, t(4;11) occurs nearly exclusively in ALL, and 85% of
cases with t(9;11) are AMLs (1, 2). Essentially all 11q23 abnor-
malities involve the ALL-1 gene (also termed MLL, HRX, or
HTRX), which rearranges with 30 partner genes to produce
fusion proteins composed of ALL-1 N terminus and the C terminus
of the partner protein (3, 4). A second and less frequent type of
ALL-1 rearrangement does not involve partner genes but rather
partial duplications of ALL-1 N-terminal segments (5). ALL-1-
associated leukemias show some unusual and intriguing features
(reviewed in refs. 6 and 7). First, they predominate infant acute
leukemias, amounting to 80% of infants with ALL and 65% of
those with AML. Second, they account for the majority of therapy-
related (secondary) leukemias, developing in 5–15% of primary
cancer patients treated with drugs, such as etoposide (VP16), that
inhibit DNA topoisomerase II. Third, in infant leukemia and in
therapy-related leukemia the disease arises after a brief latency. In
fact, studies of monozygotic twins and newborns with leukemia and
analysis of neonatal blood spots from children who were diagnosed
with leukemia indicate that in most or all infant leukemias ALL-1
rearrangements occur in utero. The short latency suggests that
ALL-1 fusion proteins induce leukemia with few, if any, additional
mutations. Fourth, prognosis of patients with 11q23 abnormalities
is dismal. Recent large studies indicated that 25% of infants and
adults 40 years old with ALL and t(4;11), or with AML and
t(9;11), were curable (1, 2, 8).
The unique biological and clinical features of 11q23-associated
leukemias, in conjunction with their induction by altered versions
of ALL-1, a highly intricate chromatin modifier (9), prompted us to
look for molecular clues for those features by examining the
expression profiles of these leukemias.
Materials and Methods
Patients, Specimens, and DNA Microarrays. Apart from two individ-
uals, all patients with 11q23 abnormalities were adults. The samples
were provided by the GIMEMA Italian Multicenter Study Group.
Informed consent was obtained from the patients. Also included in
the analysis were four AML cell lines with t(9;11) (MONO-MAC-1,
MONO-MAC-6, THP-1, and MOLM-13) and one with t(6;11)
(ML-2), and two ALL cell lines with t(4;11), RS-(4;11) and B-1.
Genes picked up in the supervised analysis, as well as most of those
pointed out as separating ALLs with and without t(4;11) in
nonsupervised analysis, had similar expression profiles in cell lines
and primary tumors. The primary tumors included 12 ALLs with
t(4;11) obtained from 10 adults, one child, and one infant, and 10
AMLs of adults, including 5 with t(9;11), 3 with ALL-1 partial
duplication, and single cases of t(10;11) and t(11;19). Controls
comprised 10 AMLs of adults, 11 ALLs of adults, and 2 ALLs of
children. Details regarding the patients the sample identifies may be
found in Table 2 and Supporting Text, which are published as
supporting information on the PNAS web site, www.pnas.org. Bone
marrow samples were obtained from newly diagnosed patients. The
samples were composed of at least 80% blasts and were subjected
to Ficoll gradient centrifugation before extraction of RNA. Details
of microarray analysis may be found in Supporting Text.
Preprocessing and Filtering of Data. The expression data were
organized in a matrix of ns  52 columns (hybridizations) and
12,600 rows (genes on the chip). Denote by Ags the ‘‘average
difference’’ of gene g in sample s. First, we thresholded the data; we
set Tgs  Ags for sizeable values, Ags  10, and replaced low values,
Ags  10, by Tgs  10. Next, log was taken, Egs  log2Tgs, and the
genes were filtered on the basis of their variation across the samples.
Denote by E gs the average of the Egs values obtained for gene g over
all ns tumor samples and by g their standard deviation. Only those
genes that satisfied g  1.1 were studied; 3,090 genes passed this
filtering procedure. After removal of non-human Affymetrix con-
trols and genes appearing on only one of the versions of the U95A
chip, we were left with 3,064 genes (of 12,600). All further analysis
was done on these genes.
Supervised Analysis. We used supervised analysis (hypothesis test-
ing) to identify genes, one at a time, whose expression levels can be
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; FDR,
false discovery rate.
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used to separate tumors into two known classes A and B of nA and
nB samples, respectively. We used the Wilcoxon rank sum test to
find genes differentially expressed between the two groups of
samples (e.g., AML samples with chromosome translocations ver-
sus those without; other comparisons are listed in Results). We used
the rank sum test because it is nonparametric, i.e., it does not
assume normal distribution of the data. For each gene g we make
the null hypothesis, according to which all nA nB expression levels
were drawn from the same distribution. The test produces a statistic
Wg and a P value for each gene g. A P value of Pg 0.05 means that
the probability of erroneously concluding that a gene does separate
the two groups is 5%, which is the standard value used in the
literature. However, here we deal with multiple comparisons; at this
level of Pg it is expected that 150 of 3,000 random, identically
distributed genes will be falsely identified as separating the two
groups of samples. To control the number of false positives, we used
the false discovery rate (FDR) method (10). The N tested genes are
ordered according to their increasing Pg values, and a parameter q,
which controls the fraction of false positives, is set. We then identify
the minimal index j such that for all i  j we have Pi  1  qN.
The null hypothesis is rejected for all genes with index i  j. This
procedure yields a list of genes for which the expected fraction of
false positives is q.
Unsupervised Analysis: Clustering. We used the coupled two-way
clustering method (11). We assume that each group of genes is
important for one particular process of interest. Thereby, the noise
generated by the large majority of genes that are not relevant for
that process is eliminated; furthermore, by using a group of
correlated genes, the noise of the individual measurements is
averaged out and reduced. The relevant subsets of genes and
samples are identified by means of an iterative process, which uses,
at each iteration level, stable gene and sample clusters that were
generated at the previous step. Before each clustering operation the
rows of the data matrix (genes) are centered (mean  0) and
normalized (SD  1). The ability to focus on stable clusters that
were generated by any clustering operation is essential for the
coupled two-way clustering method; otherwise, there would be a
computationally unfeasible number of genesample cluster pairs to
test (11). Because most clustering methods do not have a reliable
inherent stability measure for clusters, we used Superparamagnetic
Clustering (SPC), a physics-based algorithm (12) that does provide
a stability index, T(C), to each cluster C. SPC was tested on data
from a large number of problem areas including image analysis,
speech recognition, computer vision, and gene expression (refs. 11
and 12 and references therein). A parameter T controls the
resolution at which the data are viewed; as T increases, clusters
break up and the outcome is a dendrogram. A cluster C is ‘‘born’’
at T T1(C), the value of T at which its ‘‘parent’’ cluster breaks up
into two or more subclusters, one of which is C. As T increases
further, to T2(C)  T1(C), C itself breaks up and ‘‘dies’’; T(C) 
T2(C)  T1(C) is the stability index provided by SPC. The larger
T(C) is, the more statistically significant and stable (against noise
in the data and fluctuations) is the cluster C (13).
Results
Expression Profiles of ALLs with t(4;11). Leukemic cells of ALLs with
t(4;11) display features of precursor B cells with IgH rearrange-
ments, negative for CD10 and positive for CD19, but also show
some characteristics of myeloid cells (1). This and their capability
to differentiate in vitro into monocyte-like cells had suggested that
the leukemic clones originate from an early precursor cell. Hence,
this leukemia is classified as pro-B cell ALL. To determine whether
the expression repertoire of ALLs with t(4;11) is unique, we
compared it to the transcription profiles of a set of ALL samples
lacking t(4;11). These consisted of CD10 pro-B cell ALLs, Ph
chromosome-positive early pre-B cell ALLs, CD10 early pre-B
cell ALLs, and T cell ALLs. Supervised analysis indicated that at
a FDR of 0.05 there were 130 overexpressed and 107 underex-
pressed genes in ALLs with t(4;11), in comparison to ALLs lacking
the abnormality (Fig. 1A). To evaluate the consistency of the
pattern, the relative expression of each gene in all of the samples
was displayed in the form of bars (see examples in Fig. 1B). The top
genes on the lists of overexpressed or underexpressed genes in
ALLs with t(4;11) are shown in Table 1. The complete lists may be
Fig. 1. Supervised analysis of genes distinguishing ALLs with ALL-1 rearrange-
ment [t(4;11)] from other ALLs (A), and relative levels of expression of selected
genes (B). Expression levels greater and smaller than the mean 0 are shown in red
and green, respectively.
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found in Table 3, which is published as supporting information on
the PNAS web site. The clear difference in expression profiles
between ALLs with the t(4;11) abnormality and other types of
ALLs establishes that the former belong to a unique and distin-
guishable class of ALL.
Examination of the genes whose expression pattern distinguishes
t(4;11) ALLs from other ALLs reveals a substantial number of
genes associated with growth control, cell transformation, or ma-
lignancy. Those genes may be classified into several functional
categories.
1. Overexpressed oncogenes: (i) HOX A9 and MEIS1, which
form a sequence-specific DNA-binding complex (14) and are
frequently coactivated in spontaneous AML of BXH-2 mice
(15) [forced coexpression of the two genes in murine bone
marrow cells rapidly induces AML (16)]; (ii) HOX A10, which
induces AML in mice (17); (iii) LMO2 (RMBT2), whose
overexpression, resulting from chromosome translocations, is
associated with T cell ALL (18); (iv) MYC, which has a critical
role in cell proliferation and is deregulated in human lym-
phomas and other tumors (19); (v) LGALS1 (galectin1),
which cooperates with RAS in cell transformation (20) and
inhibits T cell proliferation and survival (21); and (vi)
PDGFR (platelet-derived growth factor receptor ), which
is a tyrosine kinase and is deregulated through chromosome
translocations and gene fusions in chronic myeloproliferative
diseases (22).
2. Overexpressed genes involved in drug resistance: (i) CD44,
which is associated with aggressive B-CLL (23) and conferring
resistance to several widely used anticancer drugs (24); (ii)
DHFR (dihydrofolate reductase), which confers resistance to
methotrexate; (iii) BLMH (bleomycine hydrolase); and (iv) CAT
(catalase), which protects from oxidative stress.
3. Overexpressed genes involved in protection from apoptosis and
in survival: (i) CDC2 (cell division cycle 2; p34; CDK1), which
preserves the viability of cancer cells in response to microtubule
poisons and anticancer drugs like vincristine and taxol, by
increasing expression of the apoptosis inhibitor survivin (25); (ii)
PPP2R5C (phosphatase 2A), which is implicated in regulation of
growth, transcription, and signal transduction, and is required
for survival and protects from apoptosis in Drosophila (26); (iii)
MAP3K5 (mitogen-activated protein kinase kinase kinase 5),
which is involved in activation of the p38 MAP kinase required
for initiation of the G2M checkpoint (27) and is selectively
activated in non-small cell lung cancer (28).
4. Underexpressed proapoptotic genes: (i) ITPR3 (inositol 1,4,5-
triphosphate receptor type 3), which mediates the release of
intracellular calcium and consequently actively promotes apo-
ptosis (29); (ii) IGFBP3 (IGF-binding protein 3), which has
proapoptotic activity both dependent and independent of p53
(30); and (iii) JUN, which is implicated as positive modulator of
apoptosis induced in hematopoietic progenitor cells of the
myeloid linkage (31) [down-regulation of JUN might account for
the failure of glucocorticoid therapy (32)].
Table 1. Genes most correlated with ALLs carrying the t(4;11) aberration, compared to other ALLs
No.*
Also scored as
t(4;11)-specific†
GenBank
accession
no. P value
Fold
change
Confidence
interval
Overexpressed in t(4;11) ALLs
1  D16532 VLDLR, very low density lipoprotein receptor 0.000004 17.51 (10.67–28.74)
2  U85707 MEIS1, myeloid ecotropic viral integration site 1 homolog (mouse) 0.000004 14.50 (7.64–27.51)
3  AC004080 HOXA10, homeo box A10 0.000022 10.80 (6.17–18.90)
4  AI535946 LGALS1, lectin, galactoside-binding, soluble 1 (galectin1) 0.000024 23.00 (8.82–59.98)
5  M54992 CD72 antigen 0.000037 4.35 (2.80–6.74)
6  U41813 HOXA9, homeo box A9 0.000041 20.12 (7.22–56.09)
7 AF098641 CD44, CD44 isoform (Indian blood group system) 0.000056 4.43 (2.65–7.41)
9  AA099265 RECK, reversion-inducing-cystein-rich protein with kazal motifs 0.000063 3.58 (2.03–6.31)
10  M14087 HL14, -galactoside-binding lectin 0.000068 6.94 (3.50–13.76)
11  Z69030 PPP2R5C, protein phosphatase 2, regulatory subunit B (B56),  isoform 0.000069 7.55 (3.60–15.83)
13 D83767 D8S2298E (reproduction 8) 0.000086 3.16 (2.01–4.97)
14 AF016004 GPM6B, glycoprotein M6B 0.000095 13.06 (5.98–28.53)
15 X96753 CSPG4, chondroitin sulfate proteoglycan 4 (melanoma-associated) 0.000097 7.97 (3.56–17.85)
16  D78177 QPRT, quinolinate phosphoribosyltransferase 0.000104 7.31 (3.86–13.86)
17  V00568 MYC, v-myc myelocytomatosis viral oncogene homolog (avian) 0.000126 5.93 (2.68–13.12)
18 X61118 LMO2, LIM domain only 2 (rhombotin-like 1) 0.000126 3.85 (2.05–7.22)
20  M58597 FUT4, fucosyltransferase 4 [-(1,3) fucosyltransferase, myeloid-specific] 0.000187 3.52 (2.17–5.71)
Underexpressed
131  U46922 FHIT, fragile histidine triad 0.000010 8.18 (5.16)–(12.97)
132  U70321 TNFRSF14, tumor necrosis factor receptor superfamily, member 14 0.000012 24.73 (12.05)–(50.72)
133  U01062 ITPR3, inositol 1,4,5-triphosphate receptor type 3 0.000013 10.69 (6.49)–(17.63)
134  M16594 GSTA2, glutathione S-transferase A2 0.000017 3.48 (2.27)–(5.34)
135  U03858 FLT3LG, fms-related tyrosine kinase 3 ligand 0.000024 2.24 (1.56)–(3.20)
136  AB007895 KIAA0435 0.000037 4.38 (2.47)–(7.77)
137 J05257 DPEP1, dipeptidase 1 (renal); renal metabolism of glutathione 0.000046 3.24 (2.07)–(5.07)
138  X53586 ITGA6, integrin 6 0.000056 15.57 (6.59)–(36.79)
139  J03600 ALOX5, arachidonate 5-lipoxygenase 0.000056 4.57 (2.63)–(7.94)
141  L34059 CDH4, cadherin 4, type 1, R-cadherin (retinal) 0.000069 6.89 (3.48)–(13.64)
142 AF041434 PTP4A3, protein tyrosine phosphatase type IVA, member 3 0.000085 4.11 (2.36)–(7.18)
143  X76104 DAPK1, death-associated protein kinase 1 0.000093 7.90 (3.94)–(15.85)
*Gene numbers at the left match numbers in Table 3 and appear in the same order as in Fig. 1. Missing numbers (8, 12, 19, and 140) correspond to genes that
were present more than once on the array and already appear in the table.
†Also included within the group of 43 (three genes appear twice) genes, associated with specific features of t(4;11) ALLs, in Fig. 2.
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5. Underexpressed tumor suppressors and growth inhibitors: (i)
FHIT (fragile histidine triad), which is a target of chromosome
aberrations and inactivated in many cancers, including lung,
esophagus, stomach, breast, kidney, and leukemias (33); (ii)
DAPK1 (death-associated protein kinase 1), mediating IFN	s
activity and countering oncogene-induced transformation by
activation of a p19ARFp53 apoptotic checkpoint (34); and (iii)
MADH1 (mothers against decapentaplegic homologue 1;
SMAD1), which is a transcription modulator mutated in various
forms of cancer (35).
6. Overexpressed genes acting in cell cycle progression and cell
proliferation: (i) CCNA1 (cyclin A1), which functions in S phase
and mitosis and the expression of which is elevated in a variety
of tumors including AMLs (36); (ii) BMYB (myb-like 2), which
is required for proliferation of hematopoietic cells (37) and
directly activates the antiapoptotic gene ApoJclusterin (38);
and (iii) CDKN3 (cyclin-dependent kinase inhibitor 3), which
interacts with cyclin-dependent kinases and is overexpressed in
breast and prostate cancer (39).
Our battery of ALLs lacking t(4;11) consisted of tumors at
various stages of differentiation, including pre-B, pro-B, and T cell
ALLs. Therefore, the differences in expression found should be due
in part to the differences in differentiation stage between t(4;11) to
the other ALLs. Hence, we now tried to (i) identify those genes
whose expression pattern is directly correlated with the t(4;11)
abnormality, either resulting from the abnormality or specifically
associated with the cell type in which the chromosome translocation
occurred; (ii) separate the genes above from genes whose expres-
sion reflects (sensitive to) the differences between the early and late
differentiation stages (pro-B vs. pre-B and T cell tumors); (iii)
identify genes associated with unique features of CD10 ALLs. To
this end we defined three groups of ALL samples: (i) t(4;11) tumors
(pro-B cells), (ii) CD10 tumors (pro-B cells), and (iii) the rest of
the ALLs (pre-B and T cells). Three distinct supervised analyses
were performed, which separate (i) t(4;11) ALLs from the rest of
ALLs, (ii) t(4;11) ALLs from CD10ALLs, and (iii) CD10ALLs
from the rest of the ALLs.
The genes that participate in one or more separations were
identified (see the Venn diagram of Fig. 2A). Three overlapping
groups were found, containing 77 (three genes appear twice), 43
(three genes appear twice), and 20 (one gene appears twice) genes.
Lists of the genes are in Tables 4–6, which are published as
supporting information on the PNAS web site. Each of these groups
contained genes that are overexpressed or underexpressed; the
expression matrix of the three groups is shown in Fig. 2B. Seventy-
seven genes separate both pro-B cell t(4;11) ALLs from pre-B and
T cell ALLs, as well as the latter from pro-B cell CD10 ALLs.
Having been picked in both separations, this group of 77 genes
distinguishes pro-B cell ALLs [both with and without the t(4;11)
chromosome translocation] from pre-B and T cell ALLs. The 43
genes of the second intersection simultaneously separate t(4;11)
ALLs from CD10 ALLs and from pre-B and T cell ALLs. Being
singled out in both separations, this group of genes is neither
associated with the differences between pro-B vs. pre-B and T cells
and tumors, nor does it involve specific features of CD10 tumors.
Rather, the expression of these 43 genes is affected directly by the
t(4;11) abnormality and probably by other unique features of the
pro-B cells in which the t(4;11) aberration occurred. The majority
of these 43 genes also appear in Table 1. The last group of 20 genes
separates CD10 from t(4;11) ALLs, as well as from pre-B and T
cell ALLs. Being selected in both separations, these 20 genes are
likely to be associated with unique features of CD10 tumors.
Inspection of Fig. 2B points to three t(4;11) tumors, samples 2,
6, and 14, that show a variant transcription profile. Although the
expression pattern of the 43 genes, specifically correlated with
t(4;11) ALLs, is similar in these three tumors and in the rest of
t(4;11) ALLs (see genes 81–126 of Fig. 2B), the transcription profile
of the three tumors with regard to genes 1–80 (which distinguish
pro-B from pre-B and T cell tumors) is closer to pre-B and T cell
ALLs, unlike the profile of the other 11 t(4;11) samples. The three
tumors also show some quantitative variation from the other t(4;11)
ALLs in transcription of the genes whose expression is associated
with CD10 ALLs (genes 127–147; Fig. 2B). These results suggest
the existence of two subfamilies of ALLs with the t(4;11) chromo-
some translocation, distinguished by their expression patterns.
Finally, we applied the coupled two-way clustering method (11,
12) in an unsupervised analysis. A group of 25 genes was found to
be consistently underexpressed in ALLs with t(4;11) compared with
the other ALLs (Fig. 3; Table 7, which is published as supporting
information on the PNAS web site). The cluster of samples with low
expression of these genes includes 1314 of t(4;11) and 34 of
CD10 ALLs. This is consistent with the close similarity in bio-
logical and clinical features between these two types of tumors. A
Fig. 2. Intersections of genes separating three types of ALLs (see text). (A) Three groups of genes, encompassing 77 (three appear twice), 43 (three appear twice),
and 20 (one appears twice) genes, were found to participate each in two separations. (B) The expression matrix of these three groups. Levels of expression higher or
lower than the mean 0 are shown in redyellow and blue, respectively. Arrows point to samples with variant expression profile (see text).
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second group of 132 genes separated the seven cell lines included
in the analysis from the 45 primary tumors. All these genes were
underexpressed in the cell lines (Fig. 5 and Table 8, which are
published as supporting information on the PNAS web site).
Transcription Profile of AMLs with ALL-1 Rearrangements. AMLs with
11q23 translocations and ALL-1 rearrangements were compared in
their expression profiles to AMLs with normal karyotypes. At a
FDR of 0.15 (85% confidence) we identified 66 genes overex-
pressed or underexpressed in AMLs with 11q23 abnormalities (Fig.
4; Table 9, which is published as supporting information on the
PNAS web site). Three primary AMLs with ALL-1 partial dupli-
cation (5) were compared with the other AMLs with regard to
expression of the 66 genes. Two of the three tumors resembled
AMLs without 11q23 abnormalities, whereas the third appeared
closer to the tumors with chromosome translocations (Fig. 4). The
similarity between AMLs without 11q23 aberrations and AMLs
with ALL-1 partial duplications was further evidenced in the failure
to separate the two groups at an acceptable FDR. (In parallel,
AMLs with 11q23 abnormalities were separated from AMLs with
ALL-1 partial duplications at a FDR of 0.3; some of this analysis is
shown in Fig. 6 and Table 10, which are published as supporting
information on the PNAS web site.) These results, if confirmed with
additional samples, suggest molecular differences between AMLs
triggered by recombination of the ALL-1 gene to partner genes and
AMLs triggered by ALL-1 partial duplications. The variations
might be reflected in biological and clinical features.
Examination of the list of genes most correlated with AMLs
carrying 11q23 abnormalities (Table 9) shows that some are in-
volved in cancer, proliferation, or apoptosis. These include the
overexpressed insulin receptor, which enhances DNA synthesis and
inhibits apoptosis (40), the overexpressed repair gene RAD 51,
which is up-regulated in breast and pancreatic cancers (41) and
probably increases drug resistance, the overexpressed PPP2R5C
phosphatase, the underexpressed JUNB, which up-regulates the
tumor suppressor gene p16 and represses cyclin D1 (42) and whose
knockout in mice induces myeloproliferative disease (43), the
underexpressed tumor suppressor FHIT, the underexpressed dou-
ble stranded RNA-activated protein kinase proapoptotic PRKR,
which acts in the context of IFN	s pathway and up-regulates FAS
and BAX (44), and the underexpressed DEFA1 (defensin), which
is involved in immune response.
Having identified genes differentially expressed in ALLs with
t(4;11) compared with ALLs without t(4:11) and in AMLs with
11q23 abnormalities compared with AMLs without such abnor-
malities, we intersected the results of these two tests (we used a
FDR level of 0.15 for both) to find the genes in common. We
identified 50 (two appear twice) such genes that were overexpressed
or down-regulated in the relevant tumors (Fig. 7 and Table 11,
which are published as supporting information on the PNAS web
site). For all these genes the difference was high for one type of
tumors (e.g., ALLs), but modest for the second type (e.g., AMLs).
The genes that were overexpressed in the samples with ALL-1
rearrangements included the phosphatase PPP2R5C and the
MCM4 gene, whose product is an essential component of the
prereplicative complex (45). The underexpressed genes included
FHIT and JUNB.
Discussion
Our results indicate distinct transcription profiles of ALL-1-
associated tumors. This is likely to be reflected in the unusual
clinical and biological characteristics of these tumors, such as short
latency, poor prognosis, expression of myeloid genes in ALL, etc.
Some of the genes pinpointed in our study of ALLs with t(4;11),
which were mostly in adults, were also indicated (Table 3) in our
Fig. 3. Clustering the ALL samples on the basis of their expression levels over a
cluster of 25 genes, G7 (which was obtained by the coupled two-way clustering).
(Left) The resulting dendrogram; each leaf corresponds to an ALL sample, with
t(4;11) ALLs colored red and CD10ALLs rose. (Right) The expression matrix, with
rows corresponding to samples and columns to genes. 1314 of t(4;11) samples
and 34 of CD10 ALLs are in the central cluster of samples with low expression
levels.
Fig. 4. Genes distinguishing AMLs with 11q23 chromosome translocations and
ALL-1 rearrangements (samples 1–12) from other AMLs (samples 16–25). Samples
13–15 of AMLs with ALL-1 partial duplication were not included in the supervised
analysis but were added later for the purpose of comparison.
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previous preliminary analysis (46) and in recent investigations that
dealt with ALLs from infants and children (47, 48).
Examining the genes overexpressed or underexpressed in tumors
with ALL-1 rearrangements (in particular in ALLs) indicates a
constellation of expression patterns previously associated with
andor highly favorable for malignant transformation and cancer.
This includes activation of oncogenes (MYC, HOX A9 and MEIS1,
LMO2, etc.), inactivation of tumor suppressor genes such as FHIT
and DAPK1, suppression of apoptosis by down-regulation of
proapoptotic genes and up-regulation of survival genes, suppression
of host immune response (up- and down-regulation of galectin 1
and defensin, respectively), up-regulation of genes conferring drug
resistance, such as CD44, DHFR (dihydrofolate reductase), and
BLMH (bleomycine hydrolase), and overexpression of genes in-
volved in cell proliferation (e.g., cyclin A1 and myb-like 2). Some of
the overexpressed genes we identified, like VLDL, PDGFR
(platelet-derived growth factor receptor ), HOX A9, MEIS1, and
insulin receptor, are also to be found expressed in normal hema-
topoietic stem cells (49) but the majority of genes are not. We
suggest that at least some of the genes alluded to by our study
contribute directly to the aggressive nature of the disease and to its
known resistance to therapy.
In an attempt to identify genes whose expression correlates more
strictly with the t(4;11) genotype, we removed genes that distinguish
pro-B from pre-B and T cell tumors, as well as genes associated with
the CD10 phenotype. The 43 genes left (Table 5) are closely linked
to the t(4;11) genotype and would be good candidates for future
biological experiments. Examination (Fig. 8, which is published as
supporting information on the PNAS web site) of the expression
level of the 43 genes in two other studies (47, 48) demonstrates (in
particular the investigation of Armstrong et al.) that nearly all of
these genes separate ALLs with and without ALL-1 rearrange-
ments. Therefore, the expression profile of the 43 genes distin-
guishes both adults (most patients of ours) and children (the other
two studies) with ALLs and ALL-1 rearrangements. Another
approach taken to identify genes more likely to be associated with
the pathogenesis was based on the (unproven) speculation that
ALL-1 fusion proteins trigger malignancy by a similar mechanism
in both ALLs and AMLs. Thus, we looked for genes that behave
in similar fashion (up- or down-regulated) in ALLs and AMLs with
ALL-1 rearrangements (Fig. 7). At the top of the list we find
PPP2R5C, FHIT, and JUNB.
Compartmentalization of the genes into two groups whose
expression distinguishes t(4;11) from other ALLs resulted in the
unexpected identification of two subclasses of t(4;11) tumors (Fig.
2B). The subclasses are discerned by the expression profile of the
77 genes separating pro-B from pre-B and T cell tumors. Because
t(4;11) tumors are generally considered to be pro-B cell ALLs, it is
perplexing that, with regard to genes separating pro-B from pre-B
and T cell ALLs, the smaller subclass of t(4;11) appears close to
pre-B and T cell tumors. Comparison of the clinical records of the
corresponding two subclasses of patients (Table 2; samples ht17,
ht21, and ht27 in this table show the variant profile) indicates that
in the first group there are 23 long-term survivors, but in the
second group the outcome is worse (29). How widespread the
distribution of t(4;11) patients into two groups is and whether there
is a significant correlation with survival remain to be determined.
The supervised analysis of AMLs with ALL-1 rearrangements vs.
control AMLs showed a less uniform pattern, as well as a lower
number of separating genes. This suggests that the two groups of
tumors are more heterogeneous. Unexpectedly, two of the three
AMLs with ALL-1 partial duplications showed expression profiles
resembling AML controls. The generality of this observation
should be decided by analyzing additional tumors.
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